



J Bernhard

Contact

J Bernhard

Publications (23)

Gennari A, Bernhard J, Morales S, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan M, Ribi K, Amillano Parraga K, Walshe J, Sun Z, Hasler-Strub U, Colleoni M, Kennedy M, von Moos R, Cortes J, Vidal M, Hennessy B, Jerusalem G. A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. *Ann Oncol* 2017

Pagani O, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, Moos R, Zaman K, Goldhirsch A, Pestalozzi B, Munzone E, Klingbiel D, Ruhstaller T, Nolé F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99. *Ann Oncol* 2016

Ribi K, BIG 1-98 Collaborative Group, Bernhard J, Gelber R, Price K, Goldhirsch A, Coates A, Pagani O, Cardoso F, Thürlimann B, Harvey V, Thompson A, Phillips K, Aldridge J, International Breast Cancer Study Group. Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. *Br J Cancer* 2012; 106:1618-25.

Münger-Beyeler C, Bernhard J, Rufibach K, Morant R, Schmid H. Quality of analgesic treatment in patients with advanced prostate cancer: do we do a better job now? The Swiss Group for Clinical Cancer Research (SAKK) experience. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer* 2008; 16:461-7.

Bernhard J, Coates A, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Colleoni M, Green M, Thürlimann B, Yeo W, Aebi S, Forbes J, Hürny C, Basser R, Martinelli G, Zhang J, Zahrieh D, International Breast Cancer Study Group. Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. *BJC* 2008; 98:25-33.

Ribi K, Bernhard J, Rufibach K, Thürlimann B, von Moos R, Ruhstaller T, Glaus A, Böhme C. Endocrine symptom assessment in women with breast cancer: what a simple "yes" means. *JSCC* 2007; 15:1349-56.

Borner M, Roth A, Lanz D, Brauchli P, Honegger H, Köberle D, Herrmann R, Rauch D, Saletti P, Wernli M, Popescu R, Dietrich D, Bernhard J, Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2005; 16:282-8.

Bernhard J, Goldhirsch A, Price K, Fey M, Thürlimann B, Veronesi A, Crivellari D, Rudenstam C, Snyder R, Collins J, Perey L, Forbes J, Murray E, Castiglione-Gertsch M, Gelber R, Coates A, Zahrieh D, Hürny C. Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. *BJC* 2004; 91:1893-901.

Morant R, Hering F, Hanselmann S, Gschwend A, Wernli M, Cerny T, Rochlitz C, Bauer J, Borner M, Bonomo M, Gillissen Sommer S, Dietrich D, Bernhard J, Schmid H. Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. *British journal of cancer* 2004; 90:1312-7.

Apró M, Thürlimann B, Sessa C, De Pree C, Bernhard J, Maibach R, Swiss Group for Clinical Cancer Research. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2003; 14:291-7.

Morant R, Hering F, Bauer J, Hanselmann S, Jacky E, Streit A, Forrer P, Egli F, Wernli M, Borner M, Thürlimann B, Bernhard J, Hsu Schmitz S, Schmid H. Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study. *European journal of cancer (Oxford, England : 1990)* 2002; 38:1626-32.

Pampallona S, Von Rohr E, Van Wegberg B, Bernhard J, Helwig S, Heusser P, Huerny C, Schaad R, Cerny T. Socio-demographic and medical characteristics of advanced cancer patients using conventional or complementary medicine. *Onkologie* 2002; 25:165-70.

Bernhard J, Maibach R, Thürlimann B, Sessa C, Aapro M, Swiss Group for Clinical Cancer Research. Patients' estimation of overall treatment burden: why not ask the obvious?. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2002; 20:65-72.

Von Rohr E, Pampallona S, Van Wegberg B, Hürny C, Bernhard J, Heusser P, Cerny T. Experiences in the realisation of a research project on anthroposophical medicine in patients with advanced cancer. *Schweizerische medizinische Wochenschrift* 2000; 130:1173-84.

Crivellari D, Senn H, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, Bernhard J, Bonetti M, Castiglione-Gertsch M, Gelber R, Rudenstam C, Thürlimann B, Price K, Coates A, Hürny C, Goldhirsch A. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2000; 18:1412-22.

Sabbioni M, Goldhirsch A, Herrmann R, Perey L, Bonnefoi H, Thürlimann B, Castiglione M, Bernhard J, Bacchi M, Siegrist H, Hürny C. Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment. *Breast cancer research and treatment* 2000; 59:279-87.

Morant R, Hürny C, Hanselmann S, Zulian G, Bauer J, Trinkler F, Jacky E, Thürlimann B, Fey M, Borner M, Maibach R, Bernhard J, Hering F. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK). *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2000; 11:183-8.

Bernhard J, Goldhirsch A, Bonnefoi H, Fey M, Morant R, Cavalli F, Castiglione-Gertsch M, Schmitz S, Thürlimann B, Hürny C. Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 1999; 17:1672-9.

Bernhard J, Goldhirsch A, Bonnefoi H, Fey M, Morant R, Cavalli F, Thürlimann B, Schmitz S, Castiglione-Gertsch M, Hürny C. Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK). *European journal of cancer (Oxford, England : 1990)* 1999; 35:913-20.

Sabbioni M, Goldhirsch A, Perey L, Bonnefoi H, Thürlimann B, Bernhard J, Bacchi M, Siegrist H, Hürny C, Castiglione M, Senn H. Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer* 1999; 7:149-53.

Van Wegberg B, Castiglione M, Hürny C, Bernhard J, Von Rohr E, Schaad R, Helwig S, Heusser P, Bacchi M, Cerny T. The cognitive-spiritual dimension--an important addition to the assessment of quality of life: validation of a questionnaire (SELT-M) in patients with advanced cancer. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 1998; 9:1091-6.

Bernhard J, Senn H, Goldhirsch A, Forbes J, Thürlimann B, Marini G, Galligioni E, Gelber R, Castiglione-Gertsch M, Peterson H, Coates A, Hürny C, Rudenstam C. Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG). British journal of cancer 1998; 78:686-93.

Hürny C, Van Wegberg B, Bacchi M, Bernhard J, Thürlimann B, Real O, Perey L, Bonnefoi H, Coates A. Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials. British journal of cancer 1998; 77:985-91.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch